Bayer Intellectual Property Gmbh

Lead Discovery Center Gmbh

Bayer Pharma Aktiengesellschaft

Carsten Schulz-Fademrecht

Philip Lienau

Gerhard Siemeister

Ulf Bömer

Rolf Bohlmann

Dirk Kosemund

Ulrich Lücking

Arne Scholz

Mark Jean Gnoth

Peter Nussbaumer

Jan Eickhoff

Gerd Rühter

Uwe Koch

Axel Choidas

Bert Klebl

The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase.

Pharmaceutically active disubstituted pyridine derivatives

The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase. 

Pharmaceutically active disubstituted triazine derivatives

Growing community of inventors

Dortmund, Germany

Carsten Schulz-Fademrecht